Strs Ohio Has $53.55 Million Stake in Abbott Laboratories $ABT

Strs Ohio reduced its stake in shares of Abbott Laboratories (NYSE:ABT) by 4.2% in the first quarter, HoldingsChannel.com reports. The firm owned 521,523 shares of the healthcare product maker’s stock after selling 22,871 shares during the period. Strs Ohio’s holdings in Abbott Laboratories were worth $53,545,000 as of its most recent SEC filing.

A number of other large investors also recently modified their holdings of ABT. Vanguard Group Inc. grew its holdings in Abbott Laboratories by 1.4% during the fourth quarter. Vanguard Group Inc. now owns 175,556,716 shares of the healthcare product maker’s stock worth $21,995,501,000 after buying an additional 2,402,408 shares in the last quarter. State Street Corp lifted its stake in Abbott Laboratories by 2.1% during the 4th quarter. State Street Corp now owns 79,853,782 shares of the healthcare product maker’s stock valued at $10,004,880,000 after acquiring an additional 1,627,791 shares in the last quarter. Capital International Investors boosted its holdings in Abbott Laboratories by 2.6% during the 4th quarter. Capital International Investors now owns 63,229,445 shares of the healthcare product maker’s stock worth $7,922,519,000 after acquiring an additional 1,614,706 shares during the last quarter. J. Stern & Co. LLP grew its stake in shares of Abbott Laboratories by 12,439.6% in the 4th quarter. J. Stern & Co. LLP now owns 39,319,009 shares of the healthcare product maker’s stock worth $4,926,279,000 after acquiring an additional 39,005,451 shares in the last quarter. Finally, Capital Research Global Investors raised its holdings in shares of Abbott Laboratories by 1.0% in the fourth quarter. Capital Research Global Investors now owns 39,169,239 shares of the healthcare product maker’s stock valued at $4,907,523,000 after purchasing an additional 400,400 shares during the last quarter. Institutional investors own 75.18% of the company’s stock.

Insider Activity

In other Abbott Laboratories news, Director Daniel J. Starks acquired 10,000 shares of the business’s stock in a transaction dated Monday, April 27th. The stock was bought at an average price of $92.65 per share, with a total value of $926,500.00. Following the completion of the acquisition, the director owned 6,751,103 shares of the company’s stock, valued at $625,489,692.95. This trade represents a 0.15% increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is available through this hyperlink. Also, CFO Philip P. Boudreau acquired 2,200 shares of the firm’s stock in a transaction that occurred on Thursday, April 23rd. The stock was bought at an average price of $91.50 per share, for a total transaction of $201,300.00. Following the completion of the transaction, the chief financial officer owned 2,200 shares of the company’s stock, valued at $201,300. The trade was a ∞ increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Company insiders own 0.46% of the company’s stock.

More Abbott Laboratories News

Here are the key news stories impacting Abbott Laboratories this week:

• Positive Sentiment: Robert W. Baird initiated coverage on Abbott with an “outperform” rating and a $121 price target, signaling meaningful upside from current levels. Article Title
• Positive Sentiment: Baird’s bullish view follows a broader positive analyst backdrop, with another report highlighting Abbott among Wednesday’s notable Wall Street research calls. Article Title
• Positive Sentiment: Abbott also benefited from news that Tandem Diabetes Care launched compatibility for its t:slim X2 insulin pump with Abbott’s FreeStyle Libre 3 Plus sensor in five international markets, which may support adoption of Abbott’s diabetes device ecosystem. Article Title
• Positive Sentiment: Abbott cleared a major legal risk after the DOJ ended its criminal formula probe, removing a potential overhang that had weighed on the stock. Article Title
• Neutral Sentiment: Some recent coverage compares Abbott with Intuitive Surgical as a healthcare investment idea, but this is more commentary than a direct catalyst for the shares. Article Title

Analysts Set New Price Targets

A number of research firms recently weighed in on ABT. Robert W. Baird started coverage on shares of Abbott Laboratories in a research report on Wednesday. They set an “outperform” rating and a $121.00 price target on the stock. Bank of America decreased their price objective on shares of Abbott Laboratories from $120.00 to $102.00 in a research note on Friday, June 12th. Raymond James Financial dropped their target price on shares of Abbott Laboratories from $130.00 to $115.00 and set an “outperform” rating on the stock in a research report on Friday, April 17th. Jefferies Financial Group cut their target price on Abbott Laboratories from $145.00 to $135.00 and set a “buy” rating on the stock in a research note on Friday, April 17th. Finally, Sanford C. Bernstein decreased their price target on Abbott Laboratories from $125.00 to $110.00 and set an “outperform” rating for the company in a research report on Friday, April 17th. Two equities research analysts have rated the stock with a Strong Buy rating, twenty have assigned a Buy rating, four have assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $118.42.

Abbott Laboratories Price Performance

Shares of NYSE:ABT opened at $95.25 on Friday. The company has a 50 day moving average of $88.88 and a 200 day moving average of $104.41. The company has a current ratio of 1.39, a quick ratio of 1.01 and a debt-to-equity ratio of 0.56. The stock has a market cap of $165.91 billion, a P/E ratio of 26.68, a P/E/G ratio of 1.59 and a beta of 0.61. Abbott Laboratories has a 12 month low of $81.97 and a 12 month high of $137.49.

Abbott Laboratories (NYSE:ABT) last released its quarterly earnings results on Thursday, April 16th. The healthcare product maker reported $1.15 EPS for the quarter, beating analysts’ consensus estimates of $1.14 by $0.01. Abbott Laboratories had a net margin of 13.90% and a return on equity of 17.62%. The firm had revenue of $11.16 billion during the quarter, compared to analyst estimates of $10.99 billion. During the same period in the previous year, the business earned $1.09 EPS. The business’s revenue for the quarter was up 7.8% on a year-over-year basis. Abbott Laboratories has set its FY 2026 guidance at 5.380-5.580 EPS and its Q2 2026 guidance at 1.250-1.310 EPS. As a group, sell-side analysts forecast that Abbott Laboratories will post 5.48 EPS for the current fiscal year.

Abbott Laboratories Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Monday, August 17th. Shareholders of record on Wednesday, July 15th will be paid a $0.63 dividend. This represents a $2.52 dividend on an annualized basis and a yield of 2.6%. The ex-dividend date is Wednesday, July 15th. Abbott Laboratories’s dividend payout ratio is currently 70.59%.

About Abbott Laboratories

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.